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CHAPTER I 
 
 
INTRODUCTION 
Diet and lifestyle remain principal factors in the prevention and treatment of chronic 
disease.  Epidemiologic evidence has consistently indicated fruit and vegetable 
consumption in the prevention of cardiovascular disease as well as other chronic 
diseases (1, 2).  The proposed mechanism underlying this correlation includes the high 
phytochemical content of fruits and vegetables which have been shown to exhibit 
antioxidant and immune regulatory activities in the body (3).  Phytochemicals are non-
nutritive, plant compounds that, due to their biological activity, are related to a reduced 
risk of chronic health conditions including cancer as well as cardiovascular disease (4).   
A specific chronic health condition that plagues the United States is obesity which, 
according to data collected from NHANES, affects 33.8% of Americans (5).  Obesity is 
characterized by excess adipose tissue and is associated with an increased risk of 
cardiovascular disease (CVD), osteoarthritis, type 2 diabetes mellitus (T2D) and certain 
cancers (6).  Although obesity is a risk factor for chronic disease development, it is not 
a strong predictor of CVD development alone.  However, obesity related comorbidities 
clustered together are more accurate predictors of CVD and T2D development.  This
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 clustering of co-morbitities is collectively termed metabolic syndrome and while its 
etiology is multifactoral, oxidative stress has been suggested as a contributor (7).   
Oxidative stress occurs when production of free radicals exceeds the antioxidant 
capacity of the body (8).  Free radicals are highly reactive and can induce damage to a 
variety of cells and tissues. Dietary antioxidants such as vitamins A, C and E as well as 
phytochemicals have been investigated for their role in combating oxidative stress and 
subsequent biological damage.   
Cranberries are a good source of phytochemicals including polyphenols.  Due to their 
high phytochemical content, cranberries have been the focus of research regarding 
chronic disease prevention and reduction of oxidative stress.  In fact, certain studies 
have observed improvements to certain aspects of metabolic syndrome including blood 
pressure and cholesterol with various cranberry interventions (9, 10).  However, no 
studies have examined the effects of cranberry juice supplementation in individuals 
with metabolic syndrome which was the focus of our study.   
The purpose of our study was to investigate the effects of low calorie cranberry juice 
supplementation on biomarkers of oxidative stress (oxLDL and MPO) and clinical 
features of metabolic syndrome (blood pressure, waist circumference, triglycerides, 
glucose and HDL cholesterol) in obese adults. 
The null hypotheses were: 
1. Low calorie cranberry juice supplementation will have no effects on features of 
metabolic syndrome (waist circumference, BP, HDL, blood glucose, TG) 
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2. Low calorie cranberry juice supplementation will have no effects on biomarkers 
of oxidative stress associated with metabolic syndrome.
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CHAPTER II 
 
 
REVIEW OF THE LITERATURE 
Obesity has become a growing concern worldwide as the prevalence has increased 
dramatically in the last few decades (11).  The World Health Organization (WHO) has 
defined a body mass index (BMI) over 25 kg/m2  as overweight and > 30 kg/m2 as obese 
(12). Gradual but substantial shifts in American culture and lifestyle have contributed to 
progressive incidence of obesity.  Factors such as decreased physical activity and 
overconsumption of energy dense, nutrient poor foods have all been implicated in the 
growing epidemic (13).  Obesity can have significant effects on homeostasis by altering 
blood pressure, glucose metabolism and serum lipids.  Consequently, several 
comorbidities are associated with obesity including: T2D and CVD (14).  Research has 
indicated a positive correlation between BMI and risk of developing T2D or 
dyslipidemia, a precursor to CVD (13, 15).  These related diseases can significantly 
reduce life expectancy and represent a significant challenge to public health and wellness.   
Metabolic Syndrome 
The obesity related comorbidities manifest themselves in what is commonly termed 
“metabolic syndrome”.   BMI or obesity alone are not a strong enough predictors for 
CVD risk when compared to a collection of features that characteristically alter normal
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metabolic function.  Stated simply, metabolic syndrome is a clustering of risk factors 
when present in an individual can promote the development of T2D and CVD.  In 2009, a 
joint scientific statement was released by the International Diabetes Federation Task 
Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, 
American Heart Association, World Heart Federation, International Atherosclerosis 
Society and International Association for the Study of Obesity (16).  The statement 
reviewed the existing criteria for clinical diagnosis of metabolic syndrome as 
recommended by various organizations and proposed common criteria for clinical 
diagnosis.  The new recommendations advise that three or more of the following 
constitute a diagnosis of metabolic syndrome: waist circumference varies depending upon 
population and country but for individuals of European origin: >35 inches in women, 40 
in men, triglyceride level > 150 mg/dL, HDL level < 50 mg/dL in women, 40 mg/dL in 
men, blood pressure > 130/85 mm Hg and fasting blood glucose > 100 mg/dL.  Aside 
from the diagnostic criteria, metabolic syndrome is characterized by altered lipid and 
carbohydrate metabolism, inflammation, endothelial dysfunction and abnormal oxidative 
stress (17-20).  A diagnosis of metabolic syndrome increases individual risk for 
developing T2D fivefold and doubles the risk of CVD development (21).  The collection 
of individual risk factors that were previously thought to be independent of one another is 
now revealing a more involved metabolic relationship that can result in substantial health 
problems. 
 
In regards to the basis of the diagnostic criteria, visceral obesity as measured by waist 
circumference provides a better assessment of metabolic risk as opposed to subcutaneous 
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adiposity. Visceral obesity has been indicated in the development of insulin resistance 
and the elevation of inflammatory markers that have significant vascular consequences 
(14).  Insulin resistance has been suggested as the primary connection between each of 
the diagnostic criteria of metabolic syndrome (22).  It has been suggested that the effect 
of insulin resistance on the normal metabolic state is substantial and can negatively 
impact blood pressure, cholesterol and triglyceride levels significantly enough to elevate 
CVD risk.  
Metabolic Syndrome and Oxidative Stress 
While many factors have been implied in the etiology of metabolic syndrome, research 
has indicated a strong association between oxidative stress and the aforementioned 
comorbidities related to metabolic syndrome (23).  Oxidative damage is most easily 
defined as the imbalance in the reactive species including reactive oxygen species (ROS) 
produced from normal metabolic activity, namely aerobic respiration, and the 
antioxidants that eliminate or neutralize the highly reactive free radicals.  An impaired 
balance between antioxidants and prooxidant radicals such as ROS allows for 
uncontrolled reactions between the ROS and proteins and lipids thereby inducing tissue 
damage.  Damage can include impaired endothelial cell function from lipid peroxidation, 
damage to DNA, degradation of structural proteins and inactivation of enzymes (23). 
The endogenous antioxidant defense system employs various mechanisms to reduce the 
concentration of circulating free radicals including superoxide anions, peroxides and 
hydroxyl radicals (3). These mechanisms protect the body from free radical attack and 
subsequent damage.  Mechanisms include enzymatic and non-enzymatic free radical 
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scavengers.  Enzymatic scavengers consist of: superoxide dismutase (SOD) which 
scavenges superoxide radicals, catalase (CAT) which neutralizes hydrogen peroxide 
thereby finishing the detoxification started by SOD and glutathione peroxidase (GPx) 
which neutralizes hydrogen peroxide and other organic peroxides (3, 24).  Non-
enzymatic scavengers include: vitamin C which reduces a variety of radicals, vitamin E 
that protects cell membranes from damage by trapping radicals, glutathione (GSH) and 
dietary phytonutrients among others.  If these antioxidant mechanisms become 
overwhelmed or down regulated resulting in oxidative stress, certain biomarkers present 
in the blood can be identified.  These biomarkers can include myeloperoxidase (MPO), 
oxidized LDL cholesterol and malondialdehyde (MDA). 
Markers of Oxidative Stress 
Myeloperoxidase is an enzyme secreted by activated monocytes and neutrophils that, 
once secreted, can form free radicals including ROS and RNS (25).  Furthermore, MPO 
can oxidatively modify lipids as it acts as an enzymatic catalyst in the oxidation of LDL-
C.  The formation of free radicals and the oxidation of lipids promote oxidative stress in 
the body.  Oxidized LDL-C is an important biomarker as its uptake into the endothelium 
is required for the development of atherosclerosis (26).  LDL-C must be modified by free 
radical or enzymatic oxidation in order for the atherosclerotic process to initiate.  Because 
LDL-C must be oxidized by products which promote oxidative stress, Ox-LDL-C 
provides a reasonable measure of oxidative stress in the body. MDA is an end product of 
lipid peroxidation that has been shown to have carcinogenic and mutagenic activities 
(27).  
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In regards to the role of oxidative stress in metabolic syndrome, several studies have 
highlighted the various mechanisms at play in the onset of this condition.  For example, 
when examining the biomarkers of oxidative stress in obese individuals, Furukawa et al 
found that TBARS,  a marker of lipid peroxidation, was positively correlated with both 
BMI and waist circumference (28).  Additionally, they noted an inverse correlation 
between adiponectin, a protective anti-inflammatory adipokine, and both BMI and waist 
circumference.  Furukawa et al then hypothesized that fat accumulation alone without the 
influence of hyperglycemia was enough to elevate oxidative stress ultimately leading to 
the dysregulation of adipokine production.  These factors, oxidative stress, adipokine 
dysregulation and obesity can be the beginning of a complex change in the metabolic 
state.  More recently, Girona et al reported data indicating that diabetic patients have 
elevated oxidative stress as quantified by markers of lipid peroxidation (29).  
Furthermore, oxidized LDL was positively correlated with metabolic syndrome and the 
development of atherosclerosis in diabetic patients.  These findings illustrate the health 
risks associated with both oxidative stress and metabolic syndrome.   
Fruit and Vegetable Intake and CVD 
Epidemiologic studies have frequently shown a reduced risk of CVD development with 
increasing consumption of fruits and vegetables (1).  In fact, data from the Health 
Professionals Follow-up study and Nurses Health Study with a follow up duration of 14 
years indicated that 8 servings per day of fruits and vegetables can reduce the risk of 
coronary heart disease by nearly 20% (30). Additionally, results from meta-analysis 
examining the relationship between prevalence of ischemic heart disease and fruit and 
vegetable intake showed a reduced risk of ischemic heart disease in individuals 
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consuming roughly 5 servings of fruits and vegetables daily (31).  Among the proposed 
mechanisms underlying this correlation, growing attention has been placed on the role of 
phytochemicals in the prevention of CVD.   
Phytochemicals 
 According to the USDA, plant chemicals commonly referred to as phytochemicals are 
plant components shown to promote human health by scavenging free radicals, up 
regulating immune responses and repairing injured DNA (32).  Extensive research has 
been conducted to further understand the possible mechanisms that result in positive 
health benefits from foods containing phytochemicals.  Phytochemicals can be 
categorized into various classes including carotenoids, alkaloids, phenolics, nitrogen 
containing compounds and organosulfur compounds and of the multiple classes of 
phytochemicals, phenolics including flavanoids and polyphenols have been particularly 
of interest in research regarding cardiovascular disease (33).  Phenolic compounds are 
identified by their aromatic rings with attached hydroxyl groups which provide the free 
radical scavenging potential (34).   
Flavonoid consumption is inversely associated with risk of heart disease (35).  Research 
has indicated that flavonoids and polyphenols have potent free radical scavenging 
abilities and may reduce inflammation, modify lipid profiles, reduce platelet aggregation 
and reduce blood pressure (36-39).  Foods containing polyphenols include: wine, tea, 
soybeans, vegetables and citrus fruits.  Fruits such as strawberries, raspberries, 
blueberries and cranberries are particularly rich in the subclass of flavonoids called 
anthocyanidins.  Anthocyanidin components contribute to the deep red, purple, blue or 
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black colors in berries and possess both anti-inflammatory and antioxidant activities that 
may positively benefit cardiovascular health (40, 41).    
Cranberries 
Cranberries are a good source of phenolic phytochemicals like anthocyanidins and have 
recently been under investigation regarding their effects on cardiovascular disease and 
inflammation (37).  According to the USDA, the free radical scavenging ability of 
cranberries as measured by oxygen radical absorbance capacity (ORAC) is among the 
highest of other fruits and vegetables (42).  However, as seen in Table 1, cranberries and 
cranberry products are not naturally high in antioxidant vitamins C or E.  Therefore, it 
can be assumed that the antioxidant ability observed in cranberries is due to their high 
polyphenolic concentration, as noted in Table 2.   
Many of the flavonoids present in cranberries can reduce oxidative stress by inhibiting 
prooxidant enzymes, directly scavenging free radicals and activating antioxidant enzymes 
like SOD, CAT and peroxidase in the body (41).  It is important to note, however, that 
the antioxidant activity depends greatly upon the cultivation and environmental 
circumstances and conditions that can affect the berry’s phytochemical content (40).  
These factors include but are not limited to: temperature, water and nutrient availability, 
exposure to sunlight, soil content or treatment with heavy metals and maturity of plant at 
time of harvest (43).   Although these factors can potentially alter the phytochemical 
content of cranberries, Viskelis et al found similar anthocyanin content between berries 
of four separate cultivars (40). Furthermore, there was no significant difference in the 
average radical scavenging activity of all the studied cranberry cultivars. 
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Table 1: Nutritional Profile of Cranberry Products per 1 cup 
Nutrient Whole  
Raw 
Dried 
sweetened 
   Juice                     Juice 
   unsweetened     cocktail 
    
Energy (kcal) 46.00 308.00 46.00                   137.00 
Water (g) 87.13 16.00 87.13                   218.00 
Protein (g)  0.39 0.07 0.39                       0.00 
Carbohydrate (g) 12.20 82.39 12.20                     34.21 
Fat (g) 0.13 1.37 0.13                       0.25 
Fiber (g)      4.60      5.70      0.10                      0.00 
Potassium (mg) 85.00 40.00 77.00                     35.00 
Sodium (mg) 2.00 3.00 2.00                       5.00 
Vitamin C (mg)  13.30 0.20 9.30                   107.00 
Vitamin E (mg) 1.20 1.07 1.20                       0.56 
β-Carotene (mg) 36.00 52.00 27.00                     13.00 
    
Source: USDA National Nutrient Database 
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Table 2: Flavonoid Profile of Cranberry Products 
Food Class Flavonoid Mean 
Raw  
Anthocyanidins 
 
 
Cyanidin 
 
 
41.81 
 
 Delphinidin 7.66 
 
 Peonidin 42.10 
 
Flavonols 
  
 
 Myricetin 6.78 
 
 Quercetin 15.09 
Dried, sweetened  
Anthocyanidins 
  
 
 Cyanidin 0.60 
 
 Delphinidin 0.10 
 
Flavonols 
  
 
 Myricetin 2.40 
 
Juice cocktail 
 
 
 
 
 
 
 
Juice, unsweetened 
 
 
Anthocyanidins 
 
 
Flavonols 
 
 
 
 
Flavonols 
 
Quercetin 
 
 
Cyanidin 
Delphinidin 
 
Myricetin 
Quercetin 
 
 
Myricetin 
Quercetin 
4.50 
 
 
0.38 
0.03 
 
.51 
1.27 
 
 
4.41 
16.41 
Units: mg/ 100 g edible portion                  
Source: USDA Flavonoid Database 2007 
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Cranberry Intervention: Human Studies 
Research examining the effects of phenolics and cranberries on markers of oxidative 
stress including LDL oxidation has varied and is considerably limited.  Ruel et al (2008) 
supplemented 31 healthy men with increasing doses of cranberry juice every 4 weeks for 
12 weeks following a run in period in which participants consumed a low calorie 
cranberry juice placebo (44).  Blood pressure and total cholesterol (TC), triglycerides 
(TG), very low density lipoproteins (VLDL), high density lipoprotein (HDL), low density 
lipoprotein (LDL-C) and Ox-LDL-C were measured.  Significant reductions in Ox-LDL-
C and significant increases in plasma HDL were reported although changes in LDL-C 
failed to reach significance.  Also, a reduction in plasma triglycerides that did not reach 
significance was noted.  Lee et al (2008) examined the effects of cranberry extract 
supplementation on lipid profiles of individuals with T2D (9).  In this randomized, 
placebo-controlled, double-blind study, 30 type 2 diabetic patients taking oral glucose 
lowering medication were enrolled and instructed to take 3 capsules of cranberry extract 
or placebo daily for 12 weeks.  Blood pressure was recorded and fasting blood was drawn 
at baseline and 12 weeks. HDL, LDL-C, TC, TG, Ox-LDL-C, fasting glucose, 
hemoglobin A1c (HbA1c) and C-reactive protein were assessed. This study revealed a 
significant reduction in TC and LDL-C following cranberry extract supplementation daily 
for 12 weeks.  However, no significant changes in oxidized LDL, HDL, TG or C-reactive 
protein levels were reported.  Pedersen et al conducted a postprandial study investigating 
the effects of blueberry and cranberry juice consumption on plasma antioxidant status 
(45).  Nine healthy female volunteers consumed 500 ml of either blueberry, cranberry or 
placebo juice after an overnight fast on three separate occasions one week apart. On each 
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occasion, the participant would consume a different beverage.  Blood was drawn 5 
minutes before and 30 minutes, 1, 2 and 4 hours postprandial and analyzed for 
antioxidant capacity by two different methods.  The data indicated that only the cranberry 
juice caused a significant increase in plasma antioxidant capacity although the FRAP 
value of the blueberry juice was twice that of the cranberry juice.  The increase in total 
plasma antioxidant activity was still evident at 4 hours postprandial.  While these results 
point to the free radical scavenging ability of the cranberry, it is difficult to ascertain if 
the elevation in plasma antioxidant activity can be attributed to cranberry phenolics, to 
the vitamin C with which the juice was fortified or to the combined effects of the 
antioxidants present in the cranberry juice. 
While previous studies have reported significant results regarding cranberry’s effects on 
LDL oxidation and other lipid markers for metabolic syndrome, other studies have failed 
to show significant data supporting the theory of cranberry’s phenolic cardioprotective 
ability.  Duthie et al (2006) sought to examine the effects of a 2 week cranberry juice 
supplementation on oxidative stress markers including lipid values in 20 healthy females 
(46).  Participants were asked to consume either cranberry juice or a placebo drink daily 
for two weeks. Fasting plasma was drawn at baseline, 0, 1, 2 and 3 weeks and analyzed 
for lipid profile, MDA, CAT, SOD, homocysteine and phase II enzymes: GSH and GPx.  
No changes in TC, TG, HDL or LDL were detected. Additionally, phase II enzymes, 
homocysteine and MDA were not significantly different from baseline or compared to 
placebo. 
The apparent variability of findings between these studies may be explained by 
differences in population groups being investigated.  The human intervention studies that 
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reported improvement in blood lipid profiles examined participants with average BMIs 
above 26 and with elevated waist circumference and the study by Lee et al (9) included 
individuals with T2D who were on glucose lowering medication.  The human 
intervention studies that reported no significant changes in lipid profiles involved healthy 
individuals.  The disparity among the conclusions of these studies indicates a possible 
link between health status and potential lipid lowering benefits from cranberry 
phytochemicals.  Another explanation may be the design of the studies which could have 
contributed to these effects.  Possible differences including the length of the intervention, 
analytical differences, type of cranberry product employed and the dose administered 
during the intervention may have contributed to the conflicting conclusions.  For 
example, the two intervention studies that showed positive effects of cranberry 
supplementation on lipid levels were of 12 week duration in contrast to the two 
interventions showing no effects which were either a 2 week intervention or a 
postprandial study. 
In Vitro Studies: Cranberry Juice and Extracts 
In vitro studies can provide valuable insight into the mechanisms of action underlying the 
hypothesized antioxidant activity of cranberries.  Cell culture studies have produced more 
consistent findings in regard to the hypolipidemic and free radical scavenging activity of 
cranberry phenolics compared to human studies.  One such study by Wilson et al reported 
inhibition of LDL oxidation in vivo when exposed to diluted cranberry extract (47).  This 
study obtained blood samples from 5 healthy male volunteers followed by isolation of 
LDL-C.  The LDL particles were oxidized following incubation with 0, 0.10, 0.05, 0.01 
or 0.005% of diluted cranberry juice and then analyzed for TBARS.  LDL oxidation was 
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inhibited significantly in the presence of 0.10%  diluted cranberry juice.  This study 
shows effects of cranberries to favorably modify oxidative stress; however, it must be 
noted that digestion and absorption can modify phenolic compounds and the 
bioavailability of other compounds may be limited.  Similar findings were established in 
a two part study conducted by Chu and Liu (48).  Again, blood samples were collected 
from healthy males, LDL was isolated and oxidized in the presence of varying 
concentrations of fresh cranberry extract and analyzed for oxidation.  Additionally, 
human liver cells were procured and incubated with varying concentrations of cranberry 
extract to investigate effects on LDL receptor expression and intracellular cholesterol 
levels.  Data revealed that LDL oxidation was completely inhibited with 10 mg/ml 
cranberry extract and LDL receptor expression in the hepatocyte increased over 5 fold. 
Moreover, intracellular cholesterol increased nearly 3 fold, indicating an elevation in 
cholesterol uptake and efficiency.  This study dramatically attests to the potent lipid 
modulating potential of cranberries.  
Not all in vitro studies have found such notable findings.  For example, Porter et al 
sought to determine the classes of cranberry flavonoids strongly associated with 
preventing LDL-C oxidation (49).  This study treated LDL-C isolated from human 
plasma with 6 individual phenol fractions isolated from concentrated cranberry powder.  
The plasma mixtures and control mixture were then oxidized using Cu2+ and assessed for 
oxidation of LDL-C every three minutes for 300 minutes.  The lag time between Cu2+ 
exposure and oxidation of LDL-C was assessed and reported.  Of the 6 cranberry 
phenolic fractions, only fractions containing proanthocyanidins were noted to have 
significantly different lag times of LDL-C oxidation compared to control.  The other 
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fractions which included flavonols, anthocyanidins, or cinnamic acids showed no 
significant increase lag time indicating that only proanthocyanidins in isolated form were 
capable of protecting LDL-C from oxidation.  This study demonstrates that isolated 
cranberry flavonols were not effective modifiers of LDL-C oxidation. A similar study 
investigating the effects of phenolic compounds on oxidation of LDL found that 
quercetin, a major polyphenol present in cranberries, had no effect on rates of LDL 
oxidation (50). This study similarly isolated LDL-C from 65 healthy volunteers and 
oxidized the LDL-C following treatment with 5 different concentrations of various 
isolated phenolic compounds including quercetin, catechin, hesperidin and ferulic acid.  
The LDL-C was then measured for markers of oxidative stress as quantified by TBARS.  
The data indicated no significant reduction in the oxidation of LDL-C following 
treatment with quercetin.  In fact, the researchers actually observed a prooxidant effect of 
quercetin at all concentration levels.  The researchers proposed that the chemical 
structure of quercetin was correlated to its apparent prooxidant activities at various 
concentrations particularly in the presence of Cu+ and not hydrogen peroxide. The data 
from this study support the theory that individual phytochemical supplementation may 
not be as effective as whole foods or extracts.  Since epidemiological data support the 
role of fruits and vegetables in the prevention of CVD, perhaps it is a synergistic effect of 
the various nutrients, fiber and phytochemicals in whole fruits that contributes to this 
prevention. 
Animal Studies 
Animal studies have shown interesting findings in regard to cranberry supplementation 
and CVD risk factors including its effects on vasoconstriction, hypertension, 
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hyperglycemia and dyslipidemia.  These studies provide additional insight into the 
potential effects of cranberry flavonoids on features of CVD beyond that of cell models 
as systemic effects can be observed.  Juzwiak and colleagues conducted a randomized 
controlled supplementation study in rabbits to examine the effects of quercetin 
supplementation on hyperlipidemia and development of atherosclerosis (51). Following 2 
weeks of acclimation, 30 male rabbits were assigned to one of 3 experimental groups: 
standard diet, high fat diet or high fat diet + 0.05 mg/kg/d quercetin supplementation.  
After 12 weeks, animals were fasted for 18 hours then sacrificed and TC, HDL-C, LDL-
C, VLDL-C, TG, Cyt P450 and MDA were analyzed.  Additionally, the aortic intima was 
dissected and evaluated for atherosclerotic plaques.  After evaluation, the data revealed 
that the high fat diet group had significant increases in TC, HDL-C, LDL-C, VLDL-C 
and TG compared to the control group.  However, the high fat diet + quercetin 
supplementation group had significantly reduced levels of TC, LDL-C, VLDL-C and TG 
compared to the high fat diet group.  Also, Cytochrome P450, a liver enzyme involved in 
cholesterol metabolism, was significantly reduced in the high fat diet group compared to 
controls; however, no significant changes were observed in quercetin supplemented 
rabbits.  Quercetin supplemented rabbits fed a high fat diet were noted to have lower 
MDA; however, no significant differences were observed between groups.  Additionally, 
atherosclerotic plaques were significantly developed in the high fat diet rabbits with 24.6 
+/-33.1% of the aorta covered.  However, quercetin supplemented rabbits had 
significantly less area of the intima covered by atherosclerotic plaques (0.7 +/- 1.28%) 
compared to rabbits fed solely the high fat diet.  This study indicates the hypolipidemic 
and antiatherosclerotic potential of quercetin and proposes a possible mechanism of the 
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lipid lowering effect.  The researchers hypothesized that quercetin in the high fat diet 
possibly activated cytochrome P450 as evidenced by the difference in values between 
high fat diet groups.  Cytochrome P450-dependent 7 α-hydroxylase is involved in 
cholesterol metabolism and quercetin supplementation may stimulate the conversion of 
cholesterol to bile acids thus partially explaining its hypolipidemic effect.   
Another study sought to examine the effects of cranberry juice supplementation on lipid 
profiles and antioxidant status in orchidectomized rats (52).  Orchidectomized rats were 
investigated because research has identified low male sex hormones as an independent 
risk factor for hyperlipidemia and hypercholesterolemia in men thus directly contributing 
to the risk of CVD.  This randomized control study divided 32 male rats into 
experimental groups: sham surgery + water, orchidectomy (ORX) + water, ORX + 27% 
cranberry juice or ORX + 45% cranberry juice and were sacrificed after four months.  
Antioxidant capacity, MDA, plasma and hepatic cholesterol and TG and liver SOD were 
assessed.  Data showed that compared to sham group the ORX + water group had 
significantly lowered antioxidant capacity and liver SOD and significantly higher MDA, 
cholesterol and TG.  The antioxidant capacity of cranberry supplemented groups, 
however, was not significantly different than the sham group.  Also, MDA was 
significantly reduced in a dose dependent manner with cranberry juice supplemented rats.  
While this study demonstrated the possible action of cranberry juice supplementation in 
reducing hepatic triglycerides, it was not associated with any improvements to plasma 
lipid profile.  Aside from dyslipidemia, hypertension is a major risk factor for CVD and 
thus cranberries effects on vasodilation were investigated.   
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In an ex vivo study by Maher et al, rat aortae were removed from animals and subjected 
to phenylephrine (PE) contraction and acetylcholine induced relaxation and tension was 
measured (10).  Diluted cranberry juice was added before the next contraction and 
relaxation.  The in vivo aspect of the study involved supplementing anesthetized rats with 
diluted cranberry juice to observe change in blood pressure and heart rate.  The results 
showed significant vasodilation after cranberry juice exposure.  The anesthetized rats 
showed a reduction in mean arterial blood pressure by 16% suggesting significant anti-
hypertensive and vasodilatory effects of cranberries and their phytochemicals.   A 
different study reported by Kim et al examined the effects of cranberry powder 
supplementation on biomarkers of oxidative stress (53).  In this study, rats were divided 
into 4 groups: normal diet, atherogenic diet, atherogenic diet + 2% cranberry and 
atherogenic diet + 5% cranberry.  The rats were fed ad libitum for 6 weeks and then 
sacrificed after a 12 hour fast.  Blood was taken and analyzed for lipid profile, TBARs, 
SOD, protein carbonyl and total soluble phenolic compounds.  The data revealed that 
HDL had been significantly increased in the 5% cranberry group and markers of protein 
and lipid oxidation had been significantly reduced in groups supplemented with cranberry 
powder.  Although there were no significant changes in the LDL, triglycerides, total 
cholesterol, FRAP or SOD activity, this study did show a significant potential for 
cranberry to protect other biomolecules from oxidative damage.   A different study 
evaluated the effect of quercetin on glucose uptake into pig brush border membranes 
(54).  The results of this study indicated a significant decrease of glucose uptake into the 
brushborder in the presence of quercetin and suggested competitive inhibition with 
SGLT1 as a mechanism.  This study illustrates a novel concept of the cranberry flavonoid 
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which may help control glucose absorption and transport as mediated through the glucose 
transporters (SGLTs). 
 
The aforementioned studies illustrate the growing body of evidence supporting the role of 
cranberries in wellness and health promotion.  Specifically, research has shown modest 
effects of cranberries and cranberry phenolics at improving lipid levels and markers of 
oxidative stress.  Mechanistic studies at the cellular level have not shown significant 
benefit of isolated cranberry phenolic compounds.  In fact, prooxidant effects were 
reported with isolated quercetin supplementation.  Animal studies, however, have shown 
significant positive modifications to lipid levels with quercetin supplementation and 
modest results on antioxidant status when supplementing cranberry juice.  Although 
results have been mixed, human studies have indicated a preventative role of cranberries 
as indicated by observed reductions in markers of oxidative stress as well as lipid levels.  
Studies have shown significant improvements in blood lipids in both healthy and diabetic 
subjects.  While the results of the studies offer conflicting evidence as to the efficacy of 
cranberries and their phenolics, much of the research is preliminary. Because few studies 
have focused solely on berry flavonoids and even fewer have concentrated on cranberry 
phenolics, more studies are needed to ascertain the efficacy of whole cranberry products, 
cranberry extracts and capsules.  Because cranberry products, particularly juice, are 
commonly available in the United States, the potential of cranberry juice to favorably 
modify risk factors associated with the development cardiovascular disease should be 
examined.  
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CHAPTER III 
 
 
METHODS 
Institutional Review Board Approval 
The cranberry juice supplementation study, its protocol and all procedures were approved 
by the Oklahoma State University Institutional Review Board (IRB) and were conducted 
in accordance to the guidelines of the Declaration of Helsinki.  All graduate research 
assistants (GRAs) and investigators were trained in human subject research practices and 
completed IRB training through Collaborative Institutional Training Initiative (CITI) 
prior to involvement in the study.  Additionally, all GRAs received instruction on the 
process of consenting and explaining the study protocol to participants, safe food 
handling and preparation of cranberry juice or control, subject follow up and data 
collection.  Prior to involvement or enrollment in the study, participants were instructed 
to read and sign an informed consent document.    
Subjects 
Subjects were recruited at Oklahoma State University using various media outlets.  
Advertisements were posted on the College of Human Environmental Sciences webpage 
as well as in the Oklahoma State University Headlines and flyers were posted in the 
Nutritional Sciences Department.  Interested subjects were initially screened by the 
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principal investigator via telephone questionnaire and all potential participants were 
scheduled for a screening appointment to ensure all participants met inclusion criteria.   
The initial screening consisted of blood pressure, weight, height and waist circumference 
measurements as well as blood draws.  Participants were informed of the purpose of the 
study, the protocol and any potential risks or benefits associated with participating in the 
study prior to the screening blood draw.  Additionally, participants were provided with an 
informed consent document which was read and signed before any other screening 
procedures were conducted.  Participants unable to read the informed consent document 
were read the consent by a GRA or, if necessary, were given the option to have an 
interpreter explain the consent process as well as the purpose and protocol of the study. 
Inclusion and exclusion from the study was determined by the inclusion and exclusion criteria 
based on the results of the initial screen.  Individuals were notified by phone of their 
participation status. 
Adult participants meeting the following criteria were eligible for study inclusion: 
possession of any three of the five features of metabolic syndrome as outlined in the NCEP 
guidelines (waist circumference >35 inches in women, 40 in men, triglyceride level > 150 
mg/dL, HDL level < 50 mg/dL in women, 40 mg/dL in men, blood pressure > 130/85 mm 
Hg and fasting glucose > 100 mg/dL), on stable medications and have normal white blood 
cells (WBC), platelet count, hemoglobin (Hb) as well as kidney, liver and thyroid function 
test. The exclusion criteria for our study included any form of pre-existing disease including 
diabetes, cardiovascular disease, cancer, liver or kidney diseases or anemia.  Furthermore, 
subjects who were pregnant, nursing or taking any glucose or lipid lowering medication or 
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mega doses of fish oil or antioxidant supplements were excluded from the study.  Tobacco 
usage and alcohol consumption were also criteria for exclusion.    
Study Design  
This study was a blind, cross-over control intervention. Ten subjects meeting the inclusion 
criteria were recruited and randomly assigned to either a treatment group or control group.  
Participants consumed two cups daily of placebo juice or cranberry juice for four weeks.  
Both the commercially processed and pasteurized cranberry and control juices were 
provided by Ocean Spray Cranberries Inc. (MA, USA).  The placebo juice contained no 
cranberry juice and matched the cranberry juices in terms of macronutrient content.  After 
four weeks, participants entered a two week washout period in which no treatment or 
placebo was administered.  Following the washout period, participants were switched groups 
and followed the same procedure.  Participants visited the research site three times weekly to 
pick up their supply of juice and confirm adherence. 
Anthropometrics (height, weight and waist circumference), blood pressure and blood draws 
were obtained at screen and at the end of each intervention period.  All blood draws were 
performed by a certified phlebotomist and participants were compensated $30 per blood 
draw excluding screening visit for study participation.  Participants were asked to maintain 
their usual lifestyle, diet and physical activity during the study. Participants were asked to 
complete a three day food record during screen and each intervention period.  Each weekly 
food record was to consist of one weekend day and two weekdays to provide an estimate of 
usual dietary intake.  Subjects were instructed on how to accurately report type and amount 
of food as well as classification of type of meal (snack, lunch, supper, etc.) and location.
24 
 
Materials 
Anthropometrics: Participant body weight was determined using the Health-o-Meter 
tracking scale and the Gulick II tape measure was employed to determined waist 
circumference in inches at the super iliac crest. Participant height was measured in 
centimeters using a standiometer.  
Blood Pressure: Using a portable blood pressure device, Spot Vital Signs Device, (Welch 
Allyn, Skaneateles Falls, NY) systolic and diastolic blood pressure measurements were 
recorded three separate times after a period of sitting. The average of the three 
measurements was recorded. 
Blood Draws: Following an overnight fasting period, blood was collected from participants 
using anticoagulant EDTA and serum separator tubes.  Serum samples were analyzed for 
glucose, insulin, lipid level, HbA1c, platelets, hemoglobin and hematocrit at Stillwater 
Medical Center (Stillwater, OK).  Serum and plasma samples were separated by 
centrifugation, flushed with nitrogen and stored at -80oC until analyses of oxidized LDL and 
myeloperoxidase (MPO).   
Dietary Nutrient Intakes and Cranberry Beverage Polyphenol Content: Polyphenol content 
including polyphenols, anthocyanidins and proanthocyanidins as well as macronutrient 
profiles were provided by the manufacturers of the cranberry juice and placebo drinks 
(Ocean Spray).  Food records completed by participants were analyzed to evaluate any 
dietary changes that might alter results of the trial.  Following food record submission, 
dietary analysis was completed for each participant at week one and final week of study 
participation.  Dietary analysis was completed using ESHA Food Processor 9.1.0 (ESHA 
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Research Inc., Salem, OR).  Food records were analyzed for calories, total fat, protein, 
carbohydrates, fiber, vitamins A, D, E and K as well as iron and zinc.    
Biomarkers of Oxidative Stress 
Biomarkers of oxidative stress including oxLDL (oxLDL) and myeloperoxidase (MPO) 
were measured from serum samples obtained from participants at screen, end of placebo and 
end of juice intervention.  Serum oxLDL was measured in duplicate using competitive 
ELISA (Mercodia, Uppsala, Sweden).  In this assay, oxLDL from the participant’s sample 
competed with a fixed amount of oxLDL in the well for binding of the biotin-labeled 
specific antibodies.  The biotin-labeled antibody bound to the well was then detected by 
strepdavadin following a washing step that removed components of the sample that were 
unreactive.  The wells were incubated and washed a second time then treated with 3, 3’, 5, 
5’-tetramethylbenzidine (TMB) to detect bound conjugate.  Following the addition of stop 
solution to halt the reaction, the sample was read spectrophotometrically at 450 nm using the 
Synergy HT plate reader (BioTek Instruments, Inc., Winooski, VT).   
25 µl of each sample diluted with 1,000 µl sample buffer 
 
50 µl of each sample dilution and calibrators placed in well plate in duplicate 
 
50 µl antibody (mAb) added to all wells except the blank 
 
Samples incubated at room temperature on shaker for 2 hours  
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Samples manually washed 6 times with 350 µl wash buffer 
 
100 µl enzyme conjugate added to all wells 
 
Samples incubated at room temperature on shaker for 1 hour 
 
Samples manually washed 6 times with 350 µl wash buffer 
 
200 µl Substrate TMB added to all wells 
 
Samples incubated for 15 minutes 
 
50 µl stop solution added to wells 
 
Absorbance measured at 450 nm and results calculated 
 
Serum levels of MPO were quantified from participant samples using MPO solid phase 
ELISA (Mercodia, Uppsala, Sweden).  This immunoassay directs two monoclonal 
antibodies against separate antigenic determinants on the MPO molecule.  The MPO present 
in the sample reacts with anti-MPO antibodies bound to the wells as well as to the 
peroxidase-conjugated anti-MPO antibodies present in the solution during incubation.  
Following a washing step, peroxidase conjugated anti-MPO antibodies are added and after 
the second incubation and washing, the bound conjugate is detected by 3, 3’, 5, 5’-
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tetramethylbenzidine (TMB).  Following the addition of stop solution to halt the reaction, 
the sample is read spectrophotometrically at 450 nm using the Synergy HT plate reader 
(BioTek Instruments, Inc., Winooski, VT). 
25 µl each sample diluted with 250 µl sample buffer 
 
25 µl of individually diluted samples placed in well plate in triplicate along with calibrators 
 
100 µl Assay Buffer added to all wells  
 
Samples incubated on shaker for 1 hour at room temperature  
 
Samples washed 6 times manually with 350 µl wash buffer 
 
100 µl enzyme conjugate added to all wells 
 
Samples incubated on shaker for 1 hour at room temperature 
 
Samples washed 6 times manually with 350 µl wash buffer 
 
200 µl Substrate TMB added to all wells 
 
Samples incubated for 15 minutes, with no shaking 
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50 µl stop solution added to all wells 
 
Absorbance measured at 450 nm and results calculated 
Statistical Analysis 
Repeated measures ANOVA was performed on outcome measures to determine differences 
between screen, placebo and intervention anthropometrics, features of metabolic syndrome, 
lipid profiles and biomarkers of oxidative stress.  Dietary records at screen and intervention 
were compared using paired t-tests.  Statistical significance was set at p < 0.05 (two-sided 
test) and all data analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL).  
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CHAPTER IV 
 
 
FINDINGS 
Composition of Cranberry Juice and Control Beverage 
The composition of the cranberry and control juices was provided by Ocean Spray 
Cranberries Inc. (MA, USA) and outlined in Table 3.  Both beverages were low in calories 
and contributed only an additional 40 calories to daily energy intake. While the analysis 
provided by the manufacturer did not specify micronutrient content, the cranberry juice 
beverage was reported to be high in total phenolics and anthocyanidins. 
Baseline Characteristics 
The baseline characteristics of the participants are shown in Table 4 (mean ± SD).  Ten 
participants were screened and enrolled in the study, all subjects were female with ages 
ranging from 40 to 64 years (50.5 ± 7.0).  As classified by BMI, all subjects were obese or 
overweight with a mean BMI of 39.87±7.77 kg/m2.  At screen, three participants reported 
taking multivitamin or mineral supplements and three reported taking blood pressure 
lowering medication.  For continuity, dietary supplement usage was continued throughout 
the trial.  
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Anthropometrics and Clinical Parameters As outlined in the inclusion criteria, all 
participants presented with a waist circumference of 35 inches or greater.  Throughout the 
study, no significant changes were observed in waist  
circumference, BMI or body weight.  Clinical parameters are outlined in Table 5.  Some 
features of metabolic syndrome were affected by cranberry juice supplementation including 
a significant reduction of HDL cholesterol (p = 0.024) and a significant increase in fasting 
glucose when compared to baseline (p = 0.000). Changes were observed in blood pressure 
following cranberry juice supplementation reducing systolic and diastolic blood pressure 
significantly when compared to baseline (p = 0.036, p = 0.037 respectively).  At baseline, 
systolic blood pressure met criteria for diagnosis of metabolic syndrome; yet, after cranberry 
juice intervention, systolic blood pressure was below that required for metabolic syndrome.  
Other lipoprotein levels were affected by cranberry juice supplementation with non 
significant reductions to cholesterol and LDL-C by 2.6% and 4.4% respectively.   
Biomarkers of Oxidative Stress 
Two biomarkers of oxidative stress were evaluated to determine the efficacy of cranberry 
juice as an antioxidant in individuals with metabolic syndrome.  There were no significant 
changes observed to oxidized LDL or MPO following cranberry juice intervention.  
Although oxidized LDL was reduced 21.3% following cranberry juice intervention 
compared to baseline, this reduction was not statistically significant (p = 0.205).  
Furthermore,  nonsignificant increase in MPO of 22.16% was also observed from baseline (p 
= 0.129) 
Dietary Analysis 
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From baseline to end of study, participant’s average total caloric intake decreased 12.4% 
(Table 6).  At baseline, macronutrient composition of average participant intake was 
52.27% carbohydrate, 32.16% fat and 15.57% protein.  Mean cholesterol intake did not 
change significantly over the intervention and was moderate with 276.75 ± 233.20 mg/day 
and 246.17 ± 170.26 mg/day respectively at baseline and end of intervention.  Changes in 
micronutrients from baseline to week 10 include observed decreases in total carotenoids and 
vitamin C by 85.5% ( p = 0.271) and 29.1% (p = 0.199) respectively.  Copper intake was 
increased 16.05% (p = 0.413) from baseline.  Intake of other micronutrients was not 
significantly different from baseline. In general, fiber intake was low throughout the 
intervention with mean intake meeting roughly 50% of the recommended intake for women.
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Table 3: Composition of Cranberry Juice and Placebo Beverage 
 
Placebo (per 240 ml 
serving) 
Juice (per 240 ml serving) 
Brix 4.1 oB 4.2 oB 
Calories 40 40 
Sugars: fructose 5.3 g 4.8 g 
Sugars: glucose 1.9 g 1.8 g 
Sugars: sucrose 0.1 g 0.1 g 
Sweetener: Sucralose Proprietary Proprietary 
Sweetener Acesulfame Proprietary Proprietary 
pH 2.9 g 2.9 g 
Titratable Acidity 1.44 g 1.56 g 
Acids: Quinic 0.65 g 0.72 g 
Acids: Citric 0.79 g 0.82 g  
Acids: Malic 0.55 g 0.48 g 
Ascorbic Acid (Vitamin C) 60 mg 60 mg 
Total Phenolics (by HPLC) 0 mg 229 mg 
Total Anthocyanins (by 
HPLC) 
0 mg 12.4 mg 
Cy-3-Galactoside 0 mg  3.1 mg 
Cy-3-Glucoside 0 mg 0.2 mg 
Cy-3-Arabinoside 0 mg 3.0 mg 
Pn-3-Galactoside 0 mg 3.8 mg 
Pn-3-Glucoside 0 mg 0.2 mg 
Pn-3-Arabinoside 0 mg 2.1 mg 
Proanthocyanidins (by 
DMAC) 
0 mg 119 mg 
Haze 5.1 NTU 27.2 NTU 
Color: Hunter L* 23 24 
Color: Hunter a* 49 53 
Color: Hunter b* 39 40 
Source: Ocean Spray Cranberries Inc. (MA, USA)
34 
 
Table 4: Baseline Characteristics of Participants 
Characteristics Mean  SD 
Age  50.5 7.024 
BMI (kg/m2) 39.871 7.766 
ALT (U/l) 24.2 6.512 
AST(U/l) 27.8 14.505 
BUN  13.7 3.268 
Cr 0.73 0.095 
M/F (n/n) 0/10  
Dietary supplement use (n/n) 3/10  
Medication (n/n) 3/10  
Aspirin use (n/n) 0/10  
N= 10
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Table 5: Effects of Cranberry Juice Supplementation on Clinical Features of Metabolic 
Syndrome, Glucose, Insulin and Lipids 
Clinical Features Screen Placebo  Intervention  
Glucose (mg/dL) 
 
94.8 ± 9.85 96.9 ± 9.20 102.2 ± 12.01*† 
Insulin (µU/ml) 
 
17.81 ± 9.69 16.39 ± 6.46 19.61 ± 8.46 
HOMA-IR 4.302 ± 2.65 3.986 ± 1.80 5.041 ± 2.50 
Cholesterol 
(mg/dL) 
 
201.7 ± 34.98 203 ± 36.73 196.4 ± 30.36 
Triglycerides 
(mg/dL) 
 
139.6 ± 71.05 146.1 ± 52.19 155.5 ± 69.99 
LDL-cholesterol 
(mg/dL) 
 
121.7 ± 28.17 124 ± 29.73 116.3 ± 23.03 
HDL- cholesterol 
(mg/dL) 
 
52.1 ± 6.19 49.3 ± 5.93 48.9 ± 8.24* 
VLDL (mg/dL) 27.8 ± 14.27 29.2 ± 10.47 31.2 ± 14.13 
Systolic blood 
pressure (mm Hg) 
 
131.4 ± 19.67 127 ± 15.17 126.7 ± 19.16* 
Diastolic blood 
pressure (mm Hg) 
 
82.4 ± 10.04 82.9 ± 9.45 79.2 ± 8.74* 
Waist 
circumference (cm) 
43.3 ± 3.47 43 ± 3.68 43.1 ± 3.57 
 Data Expressed as Mean ± standard deviation                                                                     
* Significantly different compared to baseline (p < 0.05)                    
†Significantly different compared to placebo (p < 0.05) 
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Table 6: Dietary Analysis of Participants’ Intake from Screen and Week 10 
Nutrient Beginning of Study  End of Study  
Energy (kcal) 2173.26 ±  1043.66 1904.49 ± 405.95 
Protein (g) 85.47 ± 32.15 68.95 ± 17.86 
Carbohydrate (g) 287.03 ± 134.48 259.47 ± 59.76 
Fiber (g) 13.67 ± 8.50 13.57 ± 9.28 
Total Fat (g) 78.50 ± 58.63 71.06 ± 28.49 
Saturated fat (g) 28.97 ± 14.96 25.07 ± 9.78 
Monounsaturated Fat 
(g) 
11.62 ± 9.03 15.36 ± 18.07 
Polyunsaturated fat (g) 6.34 ± 5.05 7.81 ± 5.65 
Cholesterol (mg) 276.75 ± 233.20 246.17 ± 170.26 
Carotenoids (RE) 519.05 ± 511.54 75.25 ± 45.17 
Vitamin C (mg) 97.09 ± 75.95 68.84 ± 56.82 
Vitamin E (mg) 6.85 ± 6.12 6.68 ± 4.57 
Iron (mg) 12.99 ± 4.93 12.21 ± 6.57 
Copper (mg) 0.68 ± 0.39 0.81 ± 0.39 
Zinc (mg) 6.95 ± 8.39 6.58 ± 5.10 
Data expressed as mean ± standard deviation           
N=4 
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Figure 1. Effects of low calorie cranberry juice supplementation on biomarkers of oxidative 
stress 
A              B 
  
(A)Oxidized LDL and (B) Myeloperoxidase            
Data presented as mean ± SD               
N=8       
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CHAPTER V 
 
 
CONCLUSION 
The present study illustrates the effects of cranberry juice supplementation on clinical 
features of metabolic syndrome and biomarkers of oxidative stress in participants.  Many 
in vitro and in vivo studies have shown the antioxidant, anti-hypertensive and anti-
hyperlipidemic properties of cranberries.   To our knowledge, our study is the first study 
to examine and report the anti-hypertensive and antioxidant impact of cranberry juice 
supplementation in individuals with metabolic syndrome.  Metabolic syndrome is 
significantly associated with increased risk of CVD morbidity most likely due to the 
increased oxidative stress and hyperlipidemia typically seen in individuals with metabolic 
syndrome (55).  Therefore, modulation of clinical parameters associated with metabolic 
syndrome by incorporating functional foods like antioxidant rich fruits and vegetables 
may reduce the risk of CVD development.   
One objective of our intervention was to examine the effect of low calorie cranberry juice 
supplementation on the clinical features of metabolic syndrome including: glucose, 
triglycerides, HDL, blood pressure and waist circumference.  Our study found no 
significant changes to TG or cholesterol. These findings are consistent with a previous 
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study in which no changes were observed in lipid profile including TG and cholesterol in 
healthy volunteers supplemented with 750 ml of cranberry juice daily for two weeks (46).  
However, it is important to note that, at baseline, participants had normal lipid profiles 
and were supplemented for only two weeks which may not be sufficient to see significant 
changes, particularly in individuals who are normolipidemic.   
Our study did observed a significant decrease in HDL following cranberry intervention 
compared to baseline (p = 0.024).  In fact, mean HDL at screen was moderate at 52.1 
mg/dL; however, following cranberry supplementation, mean HDL was 48.9 mg/dL.  The 
American Heart Association interprets HDL levels <50 mg/dL as low for women 
(www.heart.org).  Low HDL levels are associated with heart disease risk as these 
particles remove cholesterol from the arteries and deliver it to liver for excretion or 
reutilization.   In contrast to our findings, a cranberry juice intervention by Ruel et al 
found significant increases to HDL as well as a non-significant reduction in triglycerides 
in sedentary male participants (44).  The variability in findings may be attributed to 
differences in patient population, sample size or duration of study.  Ruel et al 
supplemented 31 men with increasing doses of cranberry juice over a period of 12 weeks 
while our study supplemented 10 women for 4 weeks.  It is possible that the study 
duration was not sufficient to observe significant modifications to clinical parameters or 
that other dietary or lifestyle factors may have inhibited a change from being observed.   
Data from our intervention did indicate a significant reduction to systolic (p = 0.036) and 
diastolic (p = 0.037) blood pressure compared to baseline.  Similar antihypertensive 
effects of berry flavonoids, including cranberry juice, have been well documented in 
animal models and a human intervention completed by Erlund et al observed significant 
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decreases in systolic and diastolic blood pressure following consumption of various 
berries and berry products for 8 weeks (10, 56, 57).   
Insulin resistance and related hyperglycemia have been suggested as the primary 
abnormal characteristic of metabolic syndrome (22).  It is proposed that the observed 
T2D causes metabolic alterations that result in dyslipidemia and hypertension thus 
increasing the risk of CVD.  Given this framework, glycemic control is of utmost 
importance for individuals with metabolic syndrome.  The results from our study 
indicated that blood glucose was significantly higher following cranberry intervention 
compared to both baseline (p = 0.00) and placebo (p = 0.003).  Because the cranberry 
juice and placebo beverage were nearly identical in terms of macronutrient content, these 
results were unanticipated.  Participants were not instructed to compensate for the 
additional carbohydrates the juice provided and thus may not have adjusted carbohydrate 
intake accordingly.  Furthermore, our finding differs from a study completed in type 2 
diabetic patients in which various cranberry juices and placebos were administered while 
blood glucose was monitored.  Following consumption of juices, blood glucose of 
participants who consumed the low calorie cranberry juice were not statistically different 
from baseline while those who consumed the regular juice had significantly higher 
glucose levels compared to baseline.  The low calorie juice administered in the previous 
study was a 27% low calorie juice matching the juice utilized in our study.  It seems 
unlikely that the cranberry juice was the sole cause of the observed increase in blood 
glucose levels in our study; however, future studies should instruct participants to 
compensate appropriately for additional carbohydrate consumption.    
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Oxidative stress plays a key role in the development of CVD by inducing lipid 
peroxidation.  Oxidation of LDL-C and its subsequent uptake by macrophages in the 
intima is a critical early step in the development and progression of atherosclerosis (58).  
Therefore, presence of elevated oxLDL in the serum is an indicator of lipid peroxidation 
and, consequently, a good marker of oxidative stress associated with atherogenesis.  
Although OxLDL was reduced in the serum by 25% following cranberry juice 
intervention as compared to baseline, this change was not signifcant (p = 0.205).  
However, the potential of cranberry juice to inhibit LDL-C oxidation is well documented 
in cell culture studies (47,49).   However, only one human study has reported a 
significant reduction in plasma oxLDL following cranberry juice intervention (37).  
Again, this study was a 12 week intervention with a larger cohort of 31 men.      
Myeloperoxidase (MPO) is a monocyte secreted enzyme associated with both 
inflammation and oxidative stress. Epidemiological evidence supports MPO as a risk 
factor for CVD as elevated plasma MPO is associated with as much as a 20 fold increase 
in risk of CAD (59).  MPO has the ability to oxidatively modify lipids such as LDL and 
increase production of free radicals.  Our study found no significant changes in MPO 
following cranberry juice intervention (p = 0.129).  These findings are consistent with 
another study which supplemented freeze dried blueberry beverage to participants with 
metabolic syndrome (60).  This study found no significant changes in MPO following 8 
weeks of supplementation.   
Participants were asked to maintain three day food records for each week for the duration 
of the study.  Only four participants submitted complete food records to be analyzed for 
differences between screen and end of study.  Overall, mean caloric intake did not 
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significantly differ from screen to week ten.  The macronutrient composition was within 
the recommended range advised by the Institute of Medicine (IOM) which suggests that 
45-65% of total calories should come from carbohydrate sources, 20-35% from fat, and 
10-35% from protein (61). Regarding micronutrient intake, average vitamin E, copper 
and zinc intakes were below that recommended by the IOM (62).  Analysis of other 
micronutrient intake found that although total carotenoid and vitamin C intake decreased 
85.5% and 29.1% from baseline, intake was not significantly different from baseline due 
to the small percentage of completed records. However, from those records, vitamin C 
intake at screen was higher than the RDA but was below the RDA at end of study.  Both 
vitamin C and carotenoids are principal antioxidant micronutrients which have the ability 
to reduce oxidative stress and prevent lipid peroxidation.  Decreases in intake observed 
from screen to week ten, although not significant, may have interfered with the cranberry 
juice supplementation and its biological effects.  It is possible that the lack of stable 
carotenoid antioxidant intake throughout the study may have blunted the effects of the 
cranberry juice thereby contributing to the observed non-significant data.    
 Our study was a four week crossover-control study in which participants with metabolic 
syndrome were supplemented with either cranberry juice or cranberry control beverage.  
This intervention has a variety of public health implications.  For example, both 
cranberry drinks used in the study were low calorie and did not significantly contribute to 
the daily caloric intake of participants. Although blood glucose was raised significantly 
following cranberry supplementation, 27% low calorie cranberry juice provides less 
carbohydrates than regular cranberry cocktail juices and are more palatable than 100% 
unsweetened juices.  Furthermore, the provided polyphenol content supplied by Ocean 
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Spray Cranberries Inc. (MA, USA) listed the total phenolics of the low calorie juice to be 
229 mg/240 ml. This is a considerable amount of polyphenols in view of the minimal 
caloric contribution of the juice.  Finally, the cranberry juice is affordable and widely 
available commercially.  Many Americans do not consume the recommended servings of 
fruits and vegetables each day and due to the commercial availability, considerable 
polyphenol content and minimal caloric contributions of the cranberry juice, it may be 
advisable for individuals to incorporate cranberry products, such as low calorie cranberry 
juice, into a healthy diet. 
The primary objective of our study was to examine the effects of low calorie cranberry 
juice supplementation on clinical features of metabolic syndrome and biomarkers of 
oxidative stress in obese adults.   
Our null hypotheses were: 
1. Low calorie cranberry juice supplementation will have no effects on features of 
metabolic syndrome (waist circumference, BP, HDL, blood glucose or TG) 
2. Low calorie cranberry juice supplementation will have no effects on biomarkers 
of oxidative stress associated with metabolic syndrome. 
 
Based on the results, we reject the null hypothesis that low calorie cranberry juice 
supplementation will not affect features of metabolic syndrome because HDL, systolic 
and diastolic blood pressures were significantly reduced and blood glucose levels were 
significantly increased following cranberry intervention compared to baseline.  We fail to 
reject the null hypothesis that low calorie cranberry juice supplementation will have no 
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effect on biomarkers of oxidative stress associated with metabolic syndrome.  Despite the 
downward trend noted in the OxLDL values, there were no statistically significant 
changes to OxLDL or MPO following cranberry intervention.   
Limitations of our study that must be noted include the relative small sample size, 
duration, sampling method and nature of the study.  Due to the fact that only ten 
participants were enrolled at the campus at Oklahoma State University, the results of our 
study may not be widely generalized.  Supplementation of a longer duration in a larger 
cohort may be recommended to reveal additional beneficial effects and increase validity 
of our findings.  Furthermore, dietary intake and compliance was self-reported.  Future 
studies may monitor subjects more closely to ensure adherence to intervention regimen 
and accurate completion of food records.
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Scope and Method of Study:  
Metabolic syndrome (MeS), a collection of risk factors including dyslipidemia, 
hypertension, visceral adiposity, and hyperglycemia, is also a condition associated 
with increased oxidative stress and CVD risk. Cranberry flavonoids, such as those 
present in cranberry juice, are potent antioxidants. The objective of this 
randomized crossover controlled trial was to analyze any difference in features of 
MeS and biomarkers of oxidative stress including OxLDL and MPO, in subjects 
following a 4-week intervention of low calorie cranberry juice in comparison to 
controls. 10 subjects with MeS were recruited and randomized to either cranberry 
group (2 cups of cranberry juice/day) or control group (2 cups of flavored 
juice/day) in a crossover design with a two week washout period.  
Anthropometrics, blood pressure and blood draws were obtained at screen as well 
as at the end of each intervention period. From blood draws, lipid profiles, 
oxidized LDL and myeloperoxidase (MPO) were determined. Subjects were 
asked maintain 3-day food records. Repeated measures ANOVA were performed 
to detect differences between groups at each intervention period with statistical 
significance set and 0.05. 
Findings and Conclusions:   
Significant reductions were observed in HDL as well as systolic and diastolic blood 
pressures following low calorie cranberry juice intervention compared to baseline.  
Additionally, a significant increase in blood glucose was observed following low 
calorie cranberry juice intervention compared to baseline.  No significant 
differences were observed in biomarkers of oxidative stress including OxLDL and 
MPO.  The results of the present study do not suggest that short term low calorie 
cranberry juice supplementation positively effects oxidative stress in subjects with 
metabolic syndrome.  However, the present study was a pilot study and further 
research should be conducted to examine the efficacy of low calorie cranberry 
juice at positively modifying CVD risk factors including blood pressure and lipid 
profiles. 
 
 
